03-08-2009: 454 Life Sciences, a Roche company, and Roche NimbleGen, both units of Roche Applied Science, have announced a collaboration with Eli Lilly and Company and SeqWright. The goal of this collaboration is to use genomic technologies to identify genetic variants possibly associated with various psychiatric diseases. SeqWright will utilize NimbleGen Sequence Capture technology to selectively enrich approximately 40 megabases of the human genome, which will then be comprehensively sequenced using 454 Life Sciences’ Genome Sequencer FLX System.
“Just a year ago, it would have been impossible to imagine how we could selectively sequence such a large portion of the human genome in such a fast and cost effective manner. Our goal at Lilly is to improve the outcomes of individual patients; increasing the speed at which we begin to understand the basis of disease is critical to improving those outcomes,” stated Brian Edmonds, Ph.D., Research Advisor, Global External Research and Development, Eli Lilly and Company. “We are participating in this collaboration as a way to better examine the root causes of various psychiatric diseases. If this project delivers as expected, we hope to identify new biomarkers or novel drug targets for future development of medicines to treat an array of psychiatric illnesses.”
Roche and SynenTec announced that Roche will transfer its Cellavista business to SynenTec, the German company which is the original inventor of the Cellavista System. This agreement was made as a result of the Roche Applied Science decision to focus its business, and guarantees future optim ... more
A team of researchers from Roche, including scientists from Roche Pharma Research and Early Development and Roche NimbleGen, reported in Genome Research that they have generated the first draft genome sequence of the cynomolgus monkey (Macaca fascicularis) and developed a novel microarray d ... more
The xCELLigence RTCA System of Roche is being used in the European Union’s DETECTIVE ("Detection of endpoints and biomarkers for repeated dose toxicity using in vitro systems”) Project, a joint study funded by the European Cosmetics Association (Colipa) and the European Commission, where Ro ... more
The main focus in proteomic studies is on the identification of proteins in given biological samples. Proteins isolated and separated from a given sample (e.g., whole cell lysates, blood or tissue, protein complexes) by immunoprecipitation or affinity chromatography or two-dimensional elect ... more
Transfection of cells is one of the main techniques used to influence gene expression. Most primary cells and human skeletal myoblasts (SkMC) in particular are very difficult to transfect, whereas for cell lines such as C2C12, many suitable transfection reagents and protocols are available. ... more
One of the most interesting aspects of real-time PCR based on detection of fluorophoric-labeled oligonucleotides, such as Hydrolysis probes, and Molecular Beacons, is the possibility of being able to detect conveniently multiple targets in the same PCR reaction (multiplex PCR). Ideally, a ... more
454 Life Sciences, a Roche company, and Roche NimbleGen, both units of Roche Applied Science, have announced a collaboration with Eli Lilly and Company and SeqWright. The goal of this collaboration is to use genomic technologies to identify genetic variants possibly associated with various ... more
The club moss Lycopodium serratum is a creeping, flowerless plant used in homeopathic medicine to treat a wide variety of ailments. It contains a potent brew of alkaloids that have attracted considerable scientific and medical interest. However, the plant makes many of these compounds in ex ... more
Sigma-Aldrich Corporation has entered into an agreement with the Massachusetts Institute of Technology (MIT) to serve as a scientific collaborator and distribution partner of The RNAi Consortium (TRC). The consortium is based at The Broad Institute in Boston and is comprised of seven world- ... more
Roche announced that the US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This test will help physicians make early, more accurate decisions about patient care, which may preve ... more
Roche and IBM announced an agreement to develop a nanopore-based sequencer that will directly read and decode human DNA quickly and efficiently. Focused on advancing IBM’s recently published “DNA Transistor” technology, the collaboration will take advantage of IBM’s leadership in microelect ... more
caprotec bioanalytics GmbH announced that it has successfully completed a research collaboration with F. Hoffmann-La Roche, Basel, Switzerland. Under the collaboration research agreement, caprotec used its proprietary CCMS (Capture Compound Mass Spectrometry) technology to analyze the bindi ... more
The deadly E. coli O104 strain that has killed dozens and hospitalized thousands across Europe has been sequenced using 454 Life Sciences’ benchtop GS Junior sequencing system to generate the “most accurate and detailed genetic analysis to date” of this particularly virulent strain. The seq ... more
454 Life Sciences, a Roche company, and Roche NimbleGen, both units of Roche Applied Science, have announced a collaboration with Eli Lilly and Company and SeqWright. The goal of this collaboration is to use genomic technologies to identify genetic variants possibly associated with various ... more
For many years, researchers at the Alfred Wegener Institute (AWI) for Polar and Marine Research in Bremerhaven, Germany have been studying polar and marine environments to improve our understanding of ocean-ice-atmosphere interactions and the animal and plant kingdoms of the Arctic and Anta ... more